Frequency and risk factors of ulcerative colitis associated colorectal cancer referral center experience in non-endemic area

Yıl 2025, Cilt: 7 Sayı: 2, 105 - 110, 21.03.2025

Yavuz Çağır , İlhami Yüksel

https://doi.org/10.38053/acmj.1609465

Öz

Aims: The incidence of colorectal cancer (CRC) in ulcerative colitis (UC) patients varies across different geographical regions, with limited data available from non-endemic areas for sporadic CRC. This study aimed to evaluate the CRC rates and risk factors in UC patients in a non-endemic region for sporadic CRC.
Methods: A retrospective cohort study was conducted on UC patients who had at least 6 months of follow-up between June 1993 and February 2023 at a tertiary referral center in Turkey. Risk factors for CRC development were assessed, including age at UC onset, disease duration, extent of colitis, family history of CRC, and treatment response.
Results: A total of 875 UC patients were included in the study. The median age at diagnosis was 38 years, and the median follow up period was 8.16 years. Of these patients, 133 (15.2%) had proctitis, 426 (48.7%) had left-sided colitis, and 316 (36.1%) had extensive colitis. CRC was histologically diagnosed in 5 (0.6%) UC patients, with a median UC onset age of 29.4 years and a total disease duration of 18 years. The median age at CRC diagnosis was 46 years. Three patients had extensive colitis, while two had left-sided colitis. Three patients had steroid dependence, two had thiopurine resistance, and one was biologic treatment resistant. All UC-related CRC patients had persistent mild to moderate disease activity on colonoscopy during follow-up.
Conclusion: The low incidence of UC-associated CRC in non-endemic areas may be associated with some environmental and racial factors specific to the region.

Anahtar Kelimeler

Colorectal cancer, ulcerative colitis, non-endemic area

Etik Beyan

Ethics approval The study was conducted in accordance with the ethical guidelines of the institutional research committee, the 1964 Declaration of Helsinki, and its subsequent amendments, or comparable ethical standards. The Ankara Bilkent City Hospital Scientific Research and Ethics Committee accepted the project on 25.01.2023 with approval No: E1/23/3219.

Kaynakça

• Maaser C, Sturm A, Vavricka SR, et al. ECCO-ESGAR guideline for diagnostic assessment in IBD part 1: initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis. 2019;13(2):144-164. doi:10.1093/ecco-jcc/jjy113
• Farraye FA, Odze RD, Eaden J, et al. AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology. 2010;138(2):738-745. doi:10.1053/j.gastro.2009.12.037
• Jess T, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol. 2012;10(6):639-645. doi:10.1016/j.cgh.2012.01.010
• Bye WA, Ma C, Nguyen TM, Parker CE, Jairath V, East JE. Strategies for detecting colorectal cancer in patients with inflammatory bowel disease: a cochrane systematic review and meta-analysis. Am J Gastroenterol. 2018;113(12):1801-1809. doi:10.1038/s41395-018-0354-7
• Choi CR, Bakir IA, Hart AL, Graham TA. Clonal evolution of colorectal cancer in IBD. Nat Rev Gastroenterol Hepatol. 2017;14(4):218-229. doi: 10.1038/nrgastro.2017.1
• Lakatos PL, Lakatos L. Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies. World J Gastroenterol. 2008;14(25):3937-3947. doi:10.3748/wjg.14.3937
• Dyson JK, Rutter MD. Colorectal cancer in inflammatory bowel disease: what is the real magnitude of the risk? World J Gastroenterol. 2012;18(29):3839-3848. doi:10.3748/wjg.v18.i29.3839
• Cronin KA, Scott S, Firth AU, et al. Annual report to the nation on the status of cancer, part 1: National cancer statistics. Cancer. 2022;128(24): 4251-4284. doi:10.1002/cncr.34479
• Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17-48. doi:10.3322/caac.21763
• Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med. 1990;323(18): 1228-1233. doi:10.1056/NEJM199011013231802
• Olén O, Erichsen R, Sachs MC, et al. Colorectal cancer in ulcerative colitis: a Scandinavian population-based cohort study. Lancet. 2020; 395(10218):123-131. doi:10.1016/S0140-6736(19)32545-0
• Amersi F, Agustin M, Ko CY. Colorectal cancer: epidemiology, risk factors, and health services. Clin Colon Rectal Surg. 2005;18(3):133-140. doi:10.1055/s-2005-916274
• Keller DS, Windsor A, Cohen R, Chand M. Colorectal cancer in inflammatory bowel disease: review of the evidence. Tech Coloproctol. 2019;23(1):3-13. doi:10.1007/s10151-019-1926-2
• Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Prz Gastroenterol. 2019; 14(2):89-103. doi:10.5114/pg.2018.81072
• Itzkowitz SH, Harpaz N. Diagnosis and management of dysplasia in patients with inflammatory bowel diseases. Gastroenterology. 2004; 126(6):1634-1648. doi:10.1053/j.gastro.2004.03.025
• Rogler G. Chronic ulcerative colitis and colorectal cancer. Cancer Lett. 2014;345(2):235-241. doi:10.1016/j.canlet.2013.07.032
• O'Connor PM, Lapointe TK, Beck PL, Buret AG. Mechanisms by which inflammation may increase intestinal cancer risk in inflammatory bowel disease. Inflamm Bowel Dis. 2010;16(8):1411-1420. doi:10.1002/ibd.21217
• de Campos Silva EF, Baima JP, de Barros JR, et al. Risk factors for ulcerative colitis-associated colorectal cancer: a retrospective cohort study. Medicine (Baltimore). 2020;99(32):e21686. doi:10.1097/MD. 0000000000021686
• Magro F, Gionchetti P, Eliakim R, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis. 2017;11(6):649-670. doi:10.1093/ecco-jcc/jjx008
• Annese V, Beaugerie L, Egan L, et al. European evidence-based consensus: inflammatory bowel disease and malignancies. J Crohns Colitis. 2015;9(11):945-965. doi:10.1093/ecco-jcc/jjv141
• Han YD, Al Bandar MH, Dulskas A, et al. Prognosis of ulcerative colitis colorectal cancer vs. sporadic colorectal cancer: propensity score matching analysis. BMC Surg. 2017;17(1):28. doi:10.1186/s12893-017-0224-z
• Ananthakrishnan AN, Shi HY, Tang W, et al. Systematic review and meta-analysis: phenotype and clinical outcomes of older-onset inflammatory bowel disease. J Crohns Colitis. 2016;10(10):1224-1236. doi:10.1093/ecco-jcc/jjw054
• Mañosa M, Calafat M, de Francisco R, et al. Phenotype and natural history of elderly onset inflammatory bowel disease: a multicentre, case-control study. Aliment Pharmacol Ther. 2018;47(5):605-614. doi:10.1111/apt.14494
• Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48(4):526-535. doi:10.1136/gut.48.4.526
• Kekilli M, Dagli U, Kalkan IH, et al. Low incidence of colorectal dysplasia and cancer among patients with ulcerative colitis: a Turkish referral centre study. Scand J Gastroenterol. 2010;45(4):434-439. doi:10. 3109/00365520903540830
• Ünal NG, Özütemiz Ö, Tekin F, Turan İ, Osmanoğlu N. Colorectal cancer and dysplasia risk of ulcerative colitis patients in a tertiary referral center in Turkey. Turk J Gastroenterol. 2019;30(2):139-147. doi: 10.5152/tjg.2018.18221
• Everhov ÅH, Erichsen R, Järås J, et al. Colorectal cancer in elderly-onset inflammatory bowel disease: a 1969-2017 Scandinavian register-based cohort study. Aliment Pharmacol Ther. 2022;56(7):1168-1182. doi:10. 1111/apt.17175
• Bernstein CN, Blanchard JF, Kliewer E, Wajda A. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer. 2001;91(4):854-862. doi:10.1002/1097-0142(20010215)91:4<854::aid-cncr1073>3.0.co;2-z
• Tozun N, Atug O, Imeryuz N, et al. Clinical characteristics of inflammatory bowel disease in Turkey: a multicenter epidemiologic survey. J Clin Gastroenterol. 2009;43(1):51-57. doi:10.1097/MCG. 0b013e3181574636